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In vitro studies on hexavalent chromium [Cr(VI)] indicate that reduced forms of this metal can interact
with DNA and cause mutations. Recently, Cr(VI) was shown to induce intestinal tumors in mice; however,
Cr(VI) elicited redox changes, cytotoxicity and hyperplasia – suggesting involvement of tissue injury
rather than direct mutagenesis. Moreover, toxicogenomic analyses indicated limited evidence for DNA
damage responses. Herein, we extend these toxicogenomic analyses by comparing the gene expression
patterns elicited by Cr(VI) with those of four mutagenic and four nonmutagenic carcinogens. To date, tox-
icogenomic proﬁles for mutagenic and nonmutagenic duodenal carcinogens do not exist, thus duodenal
gene changes in mice were compared to those elicited by hepatocarcinogens. Speciﬁcally, duodenal gene
changes in mice following exposure to Cr(VI) in drinking water were compared to hepatic gene changes
previously identiﬁed as potentially discriminating mutagenic and nonmutagenic hepatocarcinogens.
Using multivariate statistical analyses (including logistic regression classiﬁcation), the Cr(VI) gene
responses clustered apart from mutagenic carcinogens and closely with nonmutagenic carcinogens.
These ﬁndings are consistent with other intestinal data supporting a nonmutagenic mode of action
(MOA). These ﬁndings may be useful as part of a full weight of evidence MOA evaluation for Cr(VI)-
induced intestinal carcinogenesis. Limitations to this analysis will also be discussed.
 2012 Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
Inhalation of hexavalent chromium [Cr(VI)] has long been rec-
ognized to pose a carcinogenic risk to the lung (IARC, 1990). Oral
exposure to Cr(VI) at environmentally relevant levels has been
widely considered not to pose a cancer risk due to reduction of
Cr(VI) to poorly absorbed Cr(III) by bodily ﬂuids and cellular con-
stituents (De Flora et al., 1997; Proctor et al., 2002; US EPA,
1991). However, chronic exposure to very high levels of Cr(VI) in
drinking water resulted in intestinal neoplasms in mice in a recent
2-year bioassay (NTP, 2008). Notably, the carcinogenic Cr(VI)
concentrations in the drinking water were bright yellow and
were associated with reduced water intake due to unpalatability
(NTP, 2008; Thompson et al., 2011b). Considering that the
intestinal carcinogenesis in mice occurred at unusually high Cr(VI)c., 23501 Cinco Ranch Blvd.,
(C.M. Thompson), ghixon@
trategies.com (D.M. Proctor),
egies.com (M. Suh), jurban@
.com (M.A. Harris).
-NC-ND license.concentrations, it is critical to understand the mode of action
(MOA) of the intestinal tumors in mice because it informs the rel-
evance of these tumors to humans as well as the low-dose extrap-
olation methods employed for the derivation of Cr(VI) toxicity
criteria in various media (e.g. drinking water). To this end, a com-
prehensive research program was conducted to gather critical data
needed to inform the MOA underlying Cr(VI)-induced intestinal
carcinogenesis (Kopec et al., 2012a; Thompson et al., 2011a,b).
An important consideration in these studies is whether Cr(VI)
acts via a mutagenic or nonmutagenic MOA in the small intestine.
Mutagens interact directly with DNA and are generally thought to
exhibit a non-thresholded dose–response,1 whereas nonmutagenic
(i.e. indirect) genotoxic carcinogens and nongenotoxic carcinogens
exhibit thresholded behavior (Bolt et al., 2004; Eastmond, 2008).
As part of our research into the MOA of Cr(VI)-induced intestinal car-
cinogenesis, in vivo micronucleus formation and k-ras mutations1 However, according to US EPA (2005a), ‘‘Special attention is important when the
data support a nonlinear mode of action but there is also a suggestion of
mutagenicity. Depending on the strength of the suggestion of mutagenicity, the
assessment may justify a conclusion that mutagenicity is not operative at low doses
and focus on a nonlinear approach. . .’’.
C.M. Thompson et al. / Regulatory Toxicology and Pharmacology 64 (2012) 68–76 69were assessed in duodenal tissue sections of mice exposed to Cr(VI)
up to 90 days, and were found to be negative (Harris et al., 2012;
O’Brien et al., in preparation). Toxicogenomic evaluation of re-
sponses to Cr(VI) in the mouse small intestine indicated activation
of Nrf2 signaling at relatively low exposure concentrations (Kopec
et al., 2012a), consistent with clear alteration in cellular redox status
in similarly treated mice (Thompson et al., 2011b). Several genes in-
volved in DNA repair were elevated by day 8 of exposure to carcin-
ogenic concentrations of Cr(VI), and functional analysis indicated
enrichment of DNA repair pathways at the highest Cr(VI) concentra-
tions (Kopec et al., 2012a). Beyond transcriptional and functional
analyses, it is of interest to scientists and risk assessors to examine
whether the genomic signature/proﬁle of Cr(VI) is similar to that
of known mutagens. Due in part to the low incidence of cancer in
the small intestine (Greaves, 2007), there are insufﬁcient toxicoge-
nomic proﬁle data from the rodent small intestine with which to
compare the duodenal toxicogenomic data of mice treated with
Cr(VI). There are, however, toxicogenomic comparisons for muta-
genic and nonmutagenic carcinogens in rodent liver.
Ellinger-Ziegelbauer et al. (2005) exposed rats to carcinogenic
concentrations of eight hepatocarcinogens (four mutagenic and
four nonmutagenic) for up to 2 weeks, and identiﬁed a subset
of genes that were useful for distinguishing between mutagenic
and nonmutagenic hepatic carcinogens. In the absence of compa-
rable intestinal data, we compared the differential expression of
genes in the mouse duodenum following Cr(VI) treatment with
the differential expression reported by Ellinger-Ziegelbauer and
colleagues. To facilitate the comparison of the differential expres-
sion of genes across nine chemicals, we used data reduction tech-
niques (e.g. principal components analysis, PCA) and multivariate
analyses to make unbiased evaluation of whether Cr(VI) was sim-
ilar to the mutagenic or nonmutagenic carcinogens. The results
indicate that the expression pattern induced by Cr(VI) more clo-
sely follows that latter. These ﬁndings, notwithstanding the limi-
tations discussed herein, may be useful as part of a weight of
evidence to evaluate the MOA for Cr(VI)-induced intestinal
carcinogenesis.2. Material and methods
2.1. Animal treatments and tissue preparation
Test substance, animal husbandry, and study design have been
described in detail elsewhere (Thompson et al., 2011b). Brieﬂy, fe-
male B6C3F1 mice (Charles Rivers Laboratories International, Inc.)
were provided ad libitum access to Cr(VI), as sodium dichromate
dihydrate (SDD), in drinking water at concentrations ranging from
0.3–520 mg/L. After 7 and 90 days of exposure (referred to herein
respectively as day 8 and 91), animals were euthanized using
CO2. For toxicogenomic analyses, duodenal samples were scraped
and processed as described previously (Kopec et al., 2012a).2.2. Microarray analysis of Cr(VI) data
Details on mouse 4x44 K Agilent whole-genome oligonucleo-
tide microarrays and data analysis for SDD-elicited duodenal gene
expression at day 8 and 91 are described in Kopec et al. (2012a). In
brief, total RNA was isolated according to the manufacturer’s pro-
tocol with an additional acid phenol:chloroform extraction, resus-
pended in RNA storage solution (Ambion Inc., Austin, TX),
quantiﬁed (A260), and quality was assessed by evaluation of the
A260/A280 ratio and by visual inspection of 1 lg total RNA on a
denaturing gel. Dose-dependent changes in gene expression were
examined using mouse 4  44 K Agilent whole-genome oligonu-
cleotide microarrays (Agilent Technologies, Inc., Santa Clara, CA).All experiments were performed with three biological replicates
and independent labeling of each sample (Cy3 and Cy5, and dye
swap) for every dose group at each time point. Microarray data
were normalized using a semi-parametric approach (Eckel et al.,
2004, 2005).
2.3. Gene expression data selection for comparisons
These Cr(VI) gene expression data were compared to previously
published gene expression data for four genotoxic and four non-
genotoxic hepatic carcinogens (Ellinger-Ziegelbauer et al., 2005).
The genotoxic carcinogens were 2-nitroﬂuorene (2-NF), dimethyl-
nitrosamine (DMN), 4-(methylnitrosamino)-1-(3-pyridyl)-1-
butanone (NNK), and aﬂatoxin B1 (AB1); the nongenotoxic
carcinogens were methapyrilene (MPy), diethylstilbestrol (DES),
Wy-14643 (WY), and piperonylbutoxide (PBO). Importantly, the
four ‘‘genotoxic’’ hepatic carcinogens were characterized as induc-
ing DNA modiﬁcation and causing mutations and physical distor-
tion of DNA (Ellinger-Ziegelbauer et al., 2004, 2005), and have
been characterized as mutagens by the U.S. EPA (US EPA, 2005b;
US EPA, 2007). Thus, we will use the terminology mutagenic/non-
mutagenic as opposed to the genotoxic/nongenotoxic terminology
used by Ellinger-Ziegelbauer and colleagues. Moreover, the term
genotoxic is somewhat ambiguous. For example, WY can induce
oxidative DNA damage (i.e. genotoxicity), yet many scientists con-
sider carcinogens that work primarily through oxidative stress and
oxidative damage as nongenotoxic (Ellinger-Ziegelbauer et al.,
2005; Klaunig et al., 1998).
Treatment of rats with these eight carcinogens resulted in sig-
niﬁcant expression of 651 probe sets, corresponding to 477 non-
redundant genes, as measured by Affymetrix RG U34A arrays,
which were further grouped into 23 toxicological categories (Ellin-
ger-Ziegelbauer et al., 2005). Seven categories (comprised of 139
genes) were discussed in greater detail by Ellinger-Ziegelbauer
and colleagues: oxidative stress/DNA response (13), oxidative stress/
protein damage response (25), oxidative stress response (13), stress
response (9), regeneration (34), cell survival and/or proliferation
(25), and cell cycle progression (20). Several (but not all) of the
genes in these categories were differentially expression by the
two classes of carcinogens. Gene expression data for all 477 genes
were obtained from the Supplementary Material in Ellinger-Zieg-
elbauer et al. (2005). Data were available for 1, 3, 7 and 14 days
of exposure; however, only the 7 day exposure data were averaged
(3 replicates for DMN, NNK, AB1, MPy, DES, Wy, PBO and 2 repli-
cates for 2-NF) in order to obtain a single day 8 expression value
for each of the 139 genes for each of the 8 carcinogens.
The treatment doses employed in Ellinger-Ziegelbauer et al.
(2005) were concentrations known to be carcinogenic to rats in
longer-term bioassays; moreover, the doses also caused histopa-
thological changes in the course of their short-term study. For con-
sistency, we therefore selected the 520 mg/L SDD (182 mg/L Cr(VI))
treatment group because it is carcinogenic in a 2-year bioassay
(NTP, 2008), and elicited histopathological lesions in the mouse
duodenum at day 8 (Thompson et al., 2011b).
To allow for direct comparison between our data and those of
Ellinger-Ziegelbauer et al. (2005), 651 signiﬁcant Affymetrix rat
probes from Ellinger-Ziegelbauer et al. were converted to unique
HomoloGeneIDs using Database for Annotation, Visualization, and
Integrated Discovery and mapped to the mouse whole-genome
4  44 K Agilent array. Of the 477 unique genes, orthologous
mapping identiﬁed 395 (82%) mouse genes for which Cr(VI)-elic-
ited gene expression changes at 520 mg/L SDD were available. Of
the 139 unique genes in the 7 aforementioned categories, orthol-
ogous mapping identiﬁed 116 (83%) mouse genes for which
Cr(VI)-elicited gene expression changes at 520 mg/L SDD were
available.
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Expression data from Supplemental material in Ellinger-
Ziegelbauer and the Cr(VI) study were uploaded for transcription
factor analysis using Ingenuity Pathway Analysis (IPA) with ﬁlter-
ing criteria of 1.5-fold change in expression. Hierarchical clustering
was performed using MultiExperiment Viewer (MeV v. 4.6.0) of the
TM4 microarray software suite (Saeed et al., 2003).
2.5. Data reduction via principal components analysis (PCA)
The objective of this analysis is to use differential gene expres-
sion data from 116 orthologs to investigate the relationship (if any)
between those changes and genotoxicity for eight carcinogens with
MOAs characterized as mutagenic or nonmutagenic, and then use
that relationship as the basis for classifying a chemical for which
the genotoxicity is uncertain, Cr(VI). To reduce the dimension of
the data from the 116 inputs to a more manageable number, unro-
tated orthogonal PCA was employed – which is a standard tech-
nique for data reduction (Hair et al., 1998; Tabachnick and Fidell,
2007). The gene expression data, provided as ratios, were normal-
ized by log10 transformation, which is the natural transform for ra-
tio data (Keene, 1995). The Pearson correlation matrix amongst the
transformed variables was used as the input to the PCA. Horn’s par-
allel analysis as modiﬁed by Glorfeld (Glorfeld, 1995; Horn, 1965) –
a simulation-based test in which eigenvalues for the ﬁrst, second,
third, etc. components from a series of simulated random datasets
of the same size and number of variables as the actual data are
compared with the eigenvalues from the actual data – was used
to determine the number of components to retain. Only those com-
ponents from the actual data whose eigenvalues exceed the 95th
percentile of the values for the corresponding component from
the simulations are retained. The PCA allows the bulk of the infor-
mation from the entire set of 116 genes to be captured by a much
smaller and more manageable number of retained components,
which are themselves linear combinations of the original 116 gene
expression changes. These retained component scores served as
the inputs to the logistic regression and cluster analyses described
below. The PCA and the subsequent analyses using the retained
component scores were conducted in R (R Development Core
Team).
2.6. Logistic regression classiﬁcation analysis
The retained component scores of the four mutagenic and four
nonmutagenic carcinogens were used as inputs to a logistic regres-
sion classiﬁcation analysis. A logistic regression analysis was used
because the research question involves a dichotomous outcome
(mutagenic or nonmutagenic) and the logistic function is a
bounded function ideally suited for problems involving dichoto-
mous outcomes (Montgomery et al., 2006). The logistic regression
analysis maps the retained component scores to the genotoxicity
outcome (mutagenic vs. nonmutagenic) for the 8 carcinogens.
The parameters from this analysis were then used to assess the re-
tained component scores for Cr(VI) to determine its most probable
classiﬁcation.2
2.7. Cluster analysis
To further explore the question of whether the gene changes
associated with exposures to Cr(VI) in drinking water more closely2 For a general discussion of the use of a logistic-based classiﬁer for this purpose,
see Hastie et al. (2001). For a discussion of the mathematical superiority of a logistic-
based classiﬁer relative to another classical alternative, discriminant function
analysis, see Press and Wilson (1978).resembled those associated with known mutagenic or known non-
mutagenic carcinogens, a cluster analysis was performed using the
retained component scores for the four mutagenic and four non-
mutagenic carcinogens. The general method involved maximum
likelihood estimation via expectation maximization, with the qual-
ity of the candidate cluster solutions indexed by the Bayesian
Information Criterion (BIC).3 Models where the clusters could have
a variable size, variable shape (within the ellipse family), and vari-
able orientation were considered. With only four mutagenic and four
nonmutagenic carcinogens, the cluster analysis was limited to deter-
mining if the data comprised one cluster or two, as there were insuf-
ﬁcient data to consider models with greater numbers of clusters.
This was not a limitation because we were only interested in two
outcomes (mutagenic and nonmutagenic). The cluster analysis was
conducted using the mclust package for R (Fraley and Raftery,
2002, 2006). As with the logistic regression classiﬁer analysis, after
assessing the four mutagenic and four nonmutagenic carcinogens,
the cluster analysis solution was then used to classify Cr(VI).3. Results
3.1. Comparison of gene expression
Following treatment of rats with eight carcinogens, Ellinger-
Ziegelbauer et al. (2005) identiﬁed 477 non-redundant genes that
were signiﬁcantly altered by at least one carcinogenP 1.7-fold.
Of these 477 genes, expression values for 139 genes comprising
seven toxicological categories were provided in Table 2 of Ellin-
ger-Ziegelbauer et al. (2005). Two categories, Oxidative stress/DNA
damage response and Cell cycle progression were especially noted
as differentially affected by the two classes of carcinogens. Table 1
lists the expression values for genes in these two categories, viz.
the maximal change in gene expression after either 1, 3, 7, or
14 days of exposure. Broadly, the genes listed for Cell cycle progres-
sion as well as Apex1 were up-regulated by the nonmutagenic car-
cinogens, whereas the genes listed in their Oxidative stress/DNA
damage response category were up-regulated by mutagenic carcin-
ogens (Ellinger-Ziegelbauer et al., 2009, 2005). Listed in the center
column of Table 1 are the fold-change values after 7 days of expo-
sure to 520 mg/L SDD (182 mg/L Cr(VI)). Generally, the magnitude
and direction of change for each gene following Cr(VI) exposure is
more similar to nonmutagenic compounds.
To further compare the Cr(VI) gene changes with those of the
eight carcinogens in Ellinger-Ziegelbauer et al. (2005), we obtained
the expression values for the 7-day treatment groups from the
Supplemental material in Ellinger-Ziegelbauer et al. (2005). Of
the 477 non-redundant rat genes, 395 (82%) orthologous mouse
genes were identiﬁed (see Section 2.3). Expression data for these
395 orthologs were uploaded into IPA and subject to transcription
factor analysis. As shown in Table 2, p53 activity was predicted to
be activated in three of the four mutagenic carcinogens, but only
one of four nonmutagenic carcinogens. Notably, p53 was not pre-
dicted to be activated using this set of 395 orthologs (Table 2) or
when using the entire day 8 520 mg/L SDD microarray dataset
(data not shown).
During IPA analysis, we noted that Mdm2 was increased
P1.5-fold by all mutagenic carcinogens but was unchanged by
the nonmutagenic carcinogens at day 8. Other notable gene
changes from Table 1 are Cdkn1a, Ccng1 and Mgmt, which are all
regulated by p53 and purported to discriminate between muta-
genic and nonmutagenic carcinogens (Boverhof and Gollapudi,3 The BIC is a commonly used index of model quality that optimizes the trade-off
etween complexity and ﬁt – in essence ﬁnding the most parsimonious model that
ts the data well.b
ﬁ
Table 2
Transcription factor analysis.a
2-NF DMN NNK AB1 SDDb Mpy DES WY PBO
TP53 STAT3 TP53 RELA MYC MYCN MYCN PPARA NFE2L2
MYCN EZH2 MYCN STAT3 STAT5B MYC RELA PPARG PPARA
CDKN2A ;PPARD MED1 TP53 FOXM1 PPARA YY1 RXRA ;NFYA
RELA ;CEBPD RELA ;CEBPB MYCN ;SREBF1 NFE2L2 MYCN ;MYOD1
EZH2 TP73 GFI1 ;SMARCB1 TP53 ESRRA ;SMAD3
TP73 ;FOXO3 KEAP1 ;MYOD1 NFATC2 TFAM ;CREBBP
TRIM24 ;HNF4A ATF4 PPARGC1B ;EP300
;SMARCA4 ;MLXIPL ;PPARGC1B TRIM24
;PPARD ;TCF3 ;MLX MYC
;TCF3 ;CREBBP ;MLXIPL HSF1
;PXR ;RXRA Estrogen receptor
;CEBPA ;SREBF1 ;SPI1
;PML ;SREBF2 ;TP53
;IRF7 ;CREBBP
;Rb ;STAT1
;SMARCB1 ;IRF7
;MED1 ;CTNNB1
;PPARA
;NR1I3
;PPARGC1A
;HNF4A
PXR = PXR ligand-PXR-Retinoic acid-RXRa.
a Based on 395 orthologs, with P1.5-fold ﬁlter, day 8 data only.
b 520 mg/L SDD.
Table 1
Select Comparisons of Genes Involved in DNA Damage Response and Cell Cycle Progression.
Gene symbol Mutagensa Nonmutagensa
2-NF DMN NNK ABI SDDb MPy DES WY PBO
Cell cycle progression
Ccnb1 2.0 2.2 1.1 1.2 3.0 4.8 2.1 5.3 2.7
Top2a 1.8 2.2 1.3 1.1 3.4 2.4 1.8 3.9 3.9
Mcm6 1.7 1.7 1.1 1.2 1.4 1.8 2.2 3.4 7.8
Pcna 1.7 1.6 1.1 1.4 2.2 1.9 1.4 2.4 3.4
Cdc20 1.4 1.0 1.1 1.3 5.8 3.5 2.1 6.4 2.9
Pttg1 1.1 1.1 1.2 1.1 1.5 3.1 1.9 3.8 1.5
Tubb5 1.3 1.7 1.1 1.5 4.6 2.4 2.1 3.0 3.0
Oxidative stress/DNA damage
Mdm2 5.7 3.3 5.5 8.8 1.3 2.0 1.4 1.3 2.5
Mgmt 3.2 2.7 2.7 4.9 1.2 1.5 1.3 1.4 1.1
Cdkn1a 17.0 23.1 14.5 13.0 1.1 1.4 1.5 1.1 1.3
Ccng1 11.2 6.1 7.8 12.8 1.9 2.1 1.9 2.1 1.4
Apex1 2.6 1.2 1.2 1.1 4.9 2.1 2.3 2.3 2.0
a Gene list and fold-change expression values were obtained from Fig. 2 and Table 2 of Ellinger-Zigelbauer et al. (2005). Mutagenic and nonmutagenic carcinogens were
administered at known carcinogenic doses (based on longer-term studies) daily for up to 14 days. Italicized values represent maximum change from either 1 and/or 3 days of
exposure, whereas non-italicized values represent a maximum change after 7 or 14 days of exposure as reported in Table 2 of Ellinger-Ziegelbauer et al. (2005). All
nonmutagenic compounds elicited weak to moderate hyperplasia, whereas the mutagenic compounds produced variably hypertrophy, necrosis, and mitosis.
b Values for Cr(VI) represent changes in the duodenum after 7 days of exposure to 520 mg/L SDD (182 mg/L Cr(VI)), which induced histopathological lesions such as
hyperplasia, atrophy, and cytoplasmic vacuolization (Thompson et al., 2011b).
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The fold-change expression levels of these four genes in the mouse
duodenum after 7 and 90 days of exposure to Cr(VI) indicate that
only Ccng1 was elevatedP 1.5-fold, and only at day 8 (Fig. 1A–
B). In comparison to the eight carcinogens from Ellinger-Zieg-
elbauer et al. (2005), the gene changes for Cr(VI) were on par with
those of the four nonmutagenic carcinogens (Fig. 1C).
We expanded the gene comparisons for the nine carcinogens to
the 139 genes discussed in Ellinger-Ziegelbauer et al. (2005). Of the
139 rat genes, 116 (83%) orthologous mouse genes were identiﬁed,
and subjected to hierarchical clustering in order to better visualize
the expression data, as well as address the question of whether the
Cr(VI)-induced gene changes were more similar to mutagenic or
nonmutagenic carcinogens. The overall gene expression pattern in-
duced by Cr(VI) was more similar to the nonmutagenic carcino-
gens, however, Cr(VI) also clustered separately from the fournonmutagenic compounds as indicated by the dendrogram
(Fig. 2). The most noticeable similarities with the nonmutagenic
compounds can be seen in the categories of Oxidative Stress/Protein
Damage Response and Regeneration, whereas the most noticeable
dissimilarities with the mutagenic compounds can be seen in the
category of Oxidative Stress/DNA Response (Fig. 2).
3.2. Principal components analysis
As explained in the Material and methods, the gene expression
data following seven days of exposure to the eight carcinogens in
Ellinger-Ziegelbauer et al. (2005) and for Cr(VI) were analyzed by
PCA. Horn’s parallel analysis (Glorfeld, 1995; Horn, 1965) of the
PCA results showed that only the ﬁrst three components were sig-
niﬁcant (i.e. they had eigenvalues exceeding 95% of the eigenvalues
for the corresponding component in equivalently sized and
Fig. 1. Fold change of select genes involved in DNA damage response. Fold change
expression of Mgmt, Cdkn1a, Ccng1, and Mdm2 after 7 (A) and 90 (B) days of
exposure to varying concentrations of Cr(VI) in drinking water (Kopec et al., 2012a).
(C) Expression of these four genes after 7 days of exposure to mutagenic (DMN, 2-
NF, NNK, AB1) and nonmutagenic (WY, PBO, MPy, DES) carcinogens (Ellinger-
Ziegelbauer et al., 2005). Also shown are expression values for Cr(VI) in the 520 mg/
L treatment groups after 7 and 90 days of exposure. Note: dotted line indicates 1.5-
fold increase in expression.
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Fig. 2. Hierarchical clustering. Hierarchical clustering of 116 orthologs in seven
categories previously reported to be differentially expressed by mutagenic (DMN,
2-NF, NNK, AB1) and nonmutagenic (WY, PBO, MPy, DES) carcinogens. The
dendrogram indicates that Cr(VI) (in the form of SDD) more closely clusters with
the nonmutagenic carcinogens.
72 C.M. Thompson et al. / Regulatory Toxicology and Pharmacology 64 (2012) 68–76structured random datasets). Thus, the set of 116 ortholog expres-
sion scores was reduced to three component scores. Those three
components respectively accounted for 33.86%, 29.02%, 19.44% of
the overall variance and had standard deviations of 1.52, 1.41,
and 1.15. The fourth component had a standard deviation below1 (0.68), which is another indication (beyond the Horn’s parallel
analysis) that the fourth and all subsequent components were
Fig. 3. Cluster analysis. Cluster analysis of 116 orthologs results in the 4 mutagenic carcinogens (triangles) clustering together and apart from the 4 nonmutagenic
carcinogens (squares). The inner ellipse is the standard variance ellipse, and the outer ellipse is the 95% conﬁdence boundary. The square with crosshair represents Cr(VI).
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represented over 80% of the variance contained in the entire set of
116 values.3.3. Logistic regression classiﬁcation analysis
Using the three component scores identiﬁed based on the PCA
as independent variables and the known classiﬁcation (i.e., muta-
genic or nonmutagenic) of the eight carcinogens from Ellinger-
Ziegelbauer et al. (2005) as the dependent variable, the logistic
regression analysis showed that the ﬁrst component was signiﬁ-
cantly related to the classiﬁcation, X^2(1) = 11.09, p < 0.001. The
second and third components were not signiﬁcant. The overall
analysis provided an excellent ﬁt to the data, as a comparison of
the predicted values from the analysis to the actual classiﬁcation
of the eight carcinogens as either mutagenic or nonmutagenic re-
vealed a perfect correspondence. When the parameters from this
analysis were used to assess the retained component scores for
Cr(VI) to determine its most probable classiﬁcation, Cr(VI) was
classiﬁed as a nonmutagenic carcinogen with a probability of
nearly one (deviating in the ﬁfteenth decimal place).3.4. Cluster analysis
Because the logistic regression classiﬁcation analysis indicated
that the third principal component was not important in relation
to the distinction between mutagenic and nonmutagenic carcino-
gens, the cluster analysis focused only on the ﬁrst two component
scores. (The third component was ‘‘signiﬁcant’’ as per Horn’s paral-
lel analysis, but that signiﬁcant variance is not related to the issue
of classiﬁcation as either mutagenic or nonmutagenic.) The cluster
analysis showed that the BIC was maximized for a two cluster solu-
tion, indicating that the ﬁrst two component scores for the four
mutagenic and four nonmutagenic carcinogens formed two dis-
tinct clusters (Fig. 3). The inner ellipse is the standard variance el-
lipse, the outer ellipse is the 95% conﬁdence boundary, and the
differing symbols depict the groupings assigned by the cluster
analysis. It should be noted that the cluster analysis routine was
not supplied with information as to the classiﬁcation of each car-
cinogen as either mutagenic or nonmutagenic, but only the ﬁrst
two component scores based on the PCA of the ortholog expression
data. On that basis, the cluster analysis segregated the carcinogens
into two visibly distinct groups. The group on the left is, in fact, thefour mutagenic carcinogens, and the group on the right is the four
nonmutagenic carcinogens. With regard to Cr(VI), the cluster anal-
ysis assigns a probability of nearly one (deviating in the ninth dec-
imal place) that Cr(VI) belongs to the nonmutagenic group (Fig. 3).
3.5. Validation of logistic classiﬁer and cluster analysis performance
To validate the overall performance of the logistic regression
classiﬁer and cluster analysis techniques used to classify Cr(VI),
we ﬁrst used these techniques to classify each of the eight known
carcinogens. Speciﬁcally, we left out one of the carcinogens as a
test case, used the remaining seven cases as inputs to the logistic
regression and cluster analysis, and then used the results to classify
the eighth case. We repeated this analysis leaving out each of the
eight known cases in turn, and compared the classiﬁcations with
that ascribed by Ellinger-Ziegelbauer et al. (2005). The logistic
regression classiﬁer correctly classiﬁed all eight of the left-out
cases on the basis of the other seven, and the cluster analysis cor-
rectly classiﬁed six of the eight left-out cases. The overall perfor-
mance across these two techniques, 14 correct classiﬁcations out
of 16, is signiﬁcantly better than chance, X^2(1) = 9, p < 0 .01.4. Discussion
Kopec et al. (2012a) recently summarized the effects of Cr(VI)
on the duodenal transcriptome in mice following 7 or 90 days of
exposure in drinking water. Therein, Cr(VI) was shown to increase
the expression of several genes involved in base excision repair re-
lated to oxidative DNA damage (Sedelnikova et al., 2010) including
Ape1, Parp1, Pcna, Fen1 and Lig1. In addition, functional enrichment
analysis indicated enrichment of DNA repair pathways related to
mismatch repair (520 mg/L SDD), BRCA1 signaling (520 mg/L
SDD), and nucleotide excision repair (170 and 520 mg/L SDD) at
day 8 but not day 91. To further investigate genotoxic responses
at the transcript level, we compared the gene expression changes
induced by Cr(VI) in the duodenum with gene changes induced
by four mutagenic and four nonmutagenic hepatocarcinogens.
Duodenal transcripts were compared to liver transcripts because
the rarity of small intestinal cancer means transcript data for small
intestinal carcinogens are not readily available. Therefore, gene
expression patterns elicited by Cr(VI) in the duodenum were com-
pared to genes differentially effected by mutagenic and nonmuta-
genic hepatocarcinogens (Ellinger-Ziegelbauer et al., 2005).
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gested that the transcript changes elicited by Cr(VI) in the mouse
duodenum were not similar to the transcript changes induced by
mutagenic carcinogens in the liver. Furthermore, transcription fac-
tor analysis (Table 2) suggested that p53 signaling was activated
by 3 of 4 mutagens and only 1 of 4 nonmutagens. As p53 signaling
is well known to be activated by DNA damage, it is somewhat sur-
prising that p53 was not activated by all 4 mutagens. Nevertheless,
the observation that p53 signalingwas not predicted to be activated
by Cr(VI) at 520 mg/L SDD, suggests that Cr(VI) was not acting like a
mutagenic carcinogen. The multivariate analytical approaches
(Figs. 2 and 3) further suggest that the toxicogenomic expression
proﬁle in the duodenal epithelium following 7 days of exposure to
Cr(VI) in drinkingwatermore closely resembled the expression pro-
ﬁles of nonmutagenic hepatic carcinogens. In total, these analyses
lend support to the hypothesis that the carcinogenic MOA of Cr(VI)
in the small intestine does not involve a mutagenic MOA.
It should be stressed that these analyses do not prove that
Cr(VI) acts via a nonmutagenic MOA; however the results herein
are consistent with published evidence that Cr(VI) induces redox
changes at lower concentrations than those that caused cancer in
a 2-year bioassay (Kopec et al., 2012a; Thompson et al., 2011b),
as well as evidence that neither k-ras mutations or crypt micronu-
cleus formation could be detected in duodenal tissues of mice ex-
posed to Cr(VI) for up to 90 days (Harris et al., 2012; O’Brien et al.,
in preparation). Although oxidative DNA damage can lead to muta-
tion, this does not mean that compounds that induce oxidative
stress (e.g. WY) have a mutagenic MOA (Ellinger-Ziegelbauer
et al., 2005; Klaunig et al., 1998). It should also be recognized that
the term nonmutagenic is not synonymous with nongenotoxic. As
discussed in several recent reviews on chromium (Holmes et al.,
2008; Nickens et al., 2010; Zhitkovich, 2011), Cr(VI) may work
through epigenetic mechanisms such as altered DNA methylation.
For example, lung biopsies from workers occupationally exposed
to chromate exhibit fewer p53 point mutations than expected,
but instead show signs of chromosomal instability including re-
duced expression and hypermethylation of MutL homolog 1
(MLH1) (Hirose et al., 2002; Kondo et al., 1997). More recently,
Cr(VI) has been shown to increase methylation of histone H3 lysine
9 (H3K9) and produced time- and dose-dependent decreases in
MLH1 in vitro (Sun et al., 2009).
According to NTP, only two other chemicals tested by the NTP
program have caused increased incidences of neoplasms in the
mouse intestine, viz. captan and o-nitrotoluene (NTP, 2008). The
latter caused tumors of the large intestine (NTP, 2002), and mech-
anistic studies suggest that o-nitrotoluene (2-nitrotoluene) carcin-
ogenicity may involve oxidative DNA damage (Watanabe et al.,
2010). Captan and the structurally similar folpet induce similar
histopathological changes in the mouse duodenum as Cr(VI), are
reactive toward thiols, and have been determined to have a non-
mutagenic MOA (Cohen et al., 2010; US EPA, 2004). More recently,
it was reported that indium phosphide caused small intestinal tu-
mors in mice (Chandra et al., 2010). However, NTP characterized
the increased incidences of neoplasms of the small intestines of
male mice (from inhalation studies) as marginal and ‘‘may have
been related to exposure to indium phosphide’’ (emphases added)
(NTP, 2001). Nevertheless, lung tumors induced by indium phos-
phide are thought to involve oxidative stress (Gottschling et al.,
2001; Upham and Wagner, 2001). Thus, the chemicals inducing
intestinal tumors in mice investigated to date generally appear to
have oxidant properties that may be responsible for tumorigenesis.
Importantly, we have recently shown that Cr(VI) exposure signiﬁ-
cantly decreases the GSH/GSSG ratio in the duodenal epithelium of
mice and induces Nrf2 signaling (Kopec et al., 2012a; Thompson
et al., 2011b). Moreover, Nrf2 activation at day 91 was recently
conﬁrmed by IPA transcription factor analysis (Kopec et al., 2012b).Despite the aforementioned consistency with other ﬁndings
from our studies into the MOA for Cr(VI)-induced intestinal car-
cinogenesis (Harris et al., 2012; Kopec et al., 2012a; Thompson
et al., 2011b; O’Brien et al., in preparation), the genomic proﬁle
comparisons described herein have several limitations. First, the
microarray platforms (Affymetric vs. Agilent), speciﬁc gene
probes (60 vs. 25 nucleotide oligomers), signal normalization,
and statistical analyses differed between Kopec et al. (2012a)
and Ellinger-Ziegelbauer et al. (2005). Notably, a basic premise/
assumption in our analysis is that, for example, a 2-fold change
in gene expression in the Ellinger-Ziegelbauer et al. dataset is
‘‘equivalent’’ to a 2-fold change in the Kopec et al. dataset.
Second, the gene changes were compared across species (mouse
vs. rat). Notably, there is a federal effort to compare genomic re-
sponses to chemicals in yeast, C. elegans, zebraﬁsh embryos, and
mice in the pursuit of identifying ‘‘expression signature proﬁles’’
that can be used to predict toxicological responses in humans
(NIEHS, 2011). Thus, it is anticipated that cellular responses to
DNA damage, oxidative stress, and proliferation are likely to
be, in part, similar across species. Recent studies indicate that
basal gene expression is quite similar across species (Chan
et al., 2009; Zheng-Bradley et al., 2010). Whether this species
concordance holds for response to xenobiotics is less clear; how-
ever, our own studies conducted in mice and rats generally indi-
cate similar gene expression changes in the intestines of both
species in response to Cr(VI) (Kopec et al., 2012b). The difference
in tumor outcome in the intestine of rats and mice may arise
from overall differences in dosimetry (pharmacokinetics) rather
than pharmacodynamics (Proctor et al., in press).
While gene expression patterns appear to be similar across
species at the tissue level, the basal gene expression patterns
across tissues appear to be different – even within the same spe-
cies (Chan et al., 2009; Jonker et al., 2009; Zheng-Bradley et al.,
2010). Thus, a third uncertainty in the analyses herein is
whether differential gene responses in the liver should be com-
pared to differential gene responses in the duodenum. Jonker
et al. (2009) exposed mice to two genotoxic and nongenotoxic
carcinogens and reported that there was little overlap in the
genomic responses to the carcinogens in tissues examined (liver,
spleen, bladder, blood, and lymph nodes) using a microarray of
8205 oligonucleotides. Nevertheless, it is well accepted that
stress and DNA repair mechanisms are highly conserved across
species, and even phyla, on a structural and pathway level (Rob-
ertson et al., 2009; Taylor and Lehmann, 1998). Again, the effort
to compare genomic responses to chemicals across phyla (NIEHS,
2011) suggests that many scientists believe that some of the cel-
lular responses governing oxidative stress and DNA damage are
likely to be shared across cell types. Interestingly, analyses by
Zheng-Bradley et al. (2010) indicate that gene expression pat-
terns from different cell lines were more homogeneous than
their respective tissues of origin; the authors speculated that this
might be due to immortalization or the lower variability in cell
culture samples. Regardless of the reason(s), the fact that gene
expression proﬁles differ between cultured cells and their
tissues of origin suggest that extrapolation of gene changes from
in vitro cell models to in vivo models (i.e. body organs) may be
no less uncertain than extrapolating in vivo gene changes across
tissues.
Finally, it is worth noting that the Cr(VI) exposures associated
with lung cancer are primarily of particulate form and are associ-
ated with inﬂammation (Nickens et al., 2010). In contrast we ob-
served relatively little histological, biochemical, or genomic
evidence for inﬂammation in our studies (Kopec et al., 2012;
Thompson et al., 2011b). Therefore, we draw no conclusions about
the applicability of the ﬁndings herein pertaining to soluble Cr(VI)
in the duodenum to particulate Cr(VI) in the lung.
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This study does not attempt to identify gene changes that dis-
tinguish between mutagenic and nonmutagenic carcinogens, but
rather compare the gene changes elicited by Cr(VI) in the duode-
num to a relatively small set of genes previously shown to be dif-
ferentially expressed following exposure to mutagenic and
nonmutagenic carcinogens. Data reduction and multivariate statis-
tical analyses were used in order to remove subjectivity from these
comparisons. Notwithstanding the limitations discussed previ-
ously, the observation that the gene changes elicited by Cr(VI)
are more similar to nonmutagenic than mutagenic carcinogens is
consistent with evidence that Cr(VI) induced redox changes in
the intestine at both carcinogenic and noncarcinogenic concentra-
tions, as well as lack of evidence for micronucleus formation and
k-ras mutation after 90 days of exposure to Cr(VI) concentrations
in drinking water as high as 182 mg/L. Thus, while there is substan-
tial data (mainly from in vitro studies) that indicate Cr(VI) can
interact directly with DNA, target tissue data do not support a
mutagenic MOA for Cr(VI) in the small intestine. As part of a
weight of evidence evaluation of the MOA for Cr(VI)-induced intes-
tinal carcinogenesis, the analyses in this report add further support
to the hypothesis that the intestinal tumors in the mouse duode-
num are the result of a nonmutagenic MOA.Conﬂict of interest
None.
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